Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory study of XBIO-015 in patients with pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors

Next Previous
Trial Profile

Exploratory study of XBIO-015 in patients with pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; XBIO 015 (Primary)
  • Indications Carcinoma; Colorectal cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jul 2025 According to a Xenetic Biosciences media release, Dr. Abed Agbabrya, head of Oncology at the Bnei Zion Hospital, will act as the principal investigator and all work will be conducted at The Fund for Medical Research, Development of Infrastructure and Health services - Bnei Zion Medical Center in Israel.
  • 08 Jul 2025 Status changed from planning to recruiting, according to a X.enetic Biosciences media release
  • 08 Jul 2025 According to a Xenetic Biosciences media release, the company announced that its collaboration partner, PeriNess Ltd. has informed the Company that Bnei Zion Medical Center has commenced patient dosing in an exploratory clinical study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top